STK33 promotes hepatocellular carcinoma through binding to c-Myc. Issue 1 (14th November 2014)

• Record Type: Journal Article
• Authors: Yang, Tian; Song, Bin; Zhang, Jin; Yang, Guang-Shun; Zhang, Han; Yu, Wei-Feng; Wu, Meng-Chao; Lu, Jun-Hua; Shen, Feng
• Is Part Of: Gut. Volume 65:Issue 1(2016)
• Page Start: 124
• Page End: 133
• Publication Date: 2014-11-14
• Subjects: HEPATOCELLULAR CARCINOMA -- CANCER -- CELL BIOLOGY -- HEPATOCYTE; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2014-307545
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Objective: STK33 has been reported to play an important role in cancer cell proliferation. We investigated the role of STK33 in hepatocellular carcinoma (HCC) and its underlying mechanisms. Design: 251 patients with HCC were analysed for association between STK33 expression and clinical stage and survival rate. Tamoxifen (TAM)-inducible, hepatocyte-specific STK33 transgenic and knockout mice models were used to study the role of STK33 in liver tumorigenesis. HCC cell lines were used to study the role of STK33 in cell proliferation in vitro and in vivo. Results: STK33 expression was found to be frequently upregulated in patients with HCC. Significant associations were found between increased expression of STK33 and advanced HCC staging and shorter disease-free survival of patients. Overexpression of STK33 increased HCC cell proliferation both in vitro and in vivo, whereas suppression of STK33 inhibited this effect. Using a TAM-inducible, hepatocyte-specific STK33 transgenic mouse model, we found that overexpression of STK33 resulted in increased hepatocyte proliferation, leading to tumour cell burst. Using a TAM-inducible, hepatocyte-specific STK33 knockout mouse model, we found that, when subjected to the diethylnitrosamine (DEN) liver cancer bioassay, STK33KO flox/flox, Alb-ERT2-Cre mice exhibited a markedly lower incidence of tumour formation compared with control mice. The underlying mechanism may be that STK33 binds directly to c-Myc and increases its transcriptional activity. In particular, the C-terminus of STK33 blocks STK33/c-Myc association, downregulates HCC cell proliferation, and reduces DEN-induced liver tumour cell number and tumour size. Conclusions: STK33 plays an essential role in hepatocellular proliferation and liver tumorigenesis. The C-terminus of STK33 could be a potential therapeutic target in the treatment of patients with STK33-overexpressed HCC.